Article Text
Abstract
Objectives To identify individual characteristics associated with the adoption of injury risk reduction programmes (IRRP) and to investigate the variations in sociocognitive determinants (ie, attitudes, subjective norms, perceived behavioural control and intentions) of IRRP adoption in athletics (track and field) athletes.
Methods We conducted a cross-sectional study using an online survey sent to athletes licensed with the French Federation of Athletics to investigate their habits and sociocognitive determinants of IRRP adoption. Sociodemographic characteristics, sports practice and history of previous injuries were also recorded. Logistic regression analyses and group comparisons were performed.
Results The final sample was composed of 7715 athletes. From the multivariable analysis, competing at the highest level was positively associated with IRRP adoption (adjusted OR (AOR)=1.66; 99.9% CI 1.39 to 1.99 and AOR=1.48; 99.9% CI 1.22 to 1.80) and presenting a low number of past injuries was negatively associated with IRRP adoption (AOR=0.48; 99.9% CI 0.35 to 0.65 and AOR=0.61; 99.9% CI 0.44 to 0.84), both during their lifetime and the current season, respectively. These results were supported by higher scores of sociocognitive determinants among athletes who reported IRRP adoption compared with other athletes.
Conclusion Some characteristics of athletes seem to be associated with IRRP adoption either positively (competing at the highest level) or negatively (presenting a lower number of past injuries), whereas all the sociocognitive determinants tested appear to be linked to IRRP adoption. Since many athlete characteristics are difficult or impossible to change, IRRP promotion may be enhanced by targeting athletes’ beliefs and intentions to adopt an IRRP.
- athletes
- behaviour
- athletic injuries
- preventive medicine
Data availability statement
Data are available upon reasonable request. Please contact the corresponding author. Data availability statement: Data are available upon reasonable request. Please contact the corresponding author.
Statistics from Altmetric.com
Data availability statement
Data are available upon reasonable request. Please contact the corresponding author. Data availability statement: Data are available upon reasonable request. Please contact the corresponding author.
Footnotes
Twitter @Evertverhagen
Contributors PE, MS and AR conceived and designed the study and proposed the study protocol. SM, CH, LJ and EV provided revisions on the study protocol. AR performed data analyses and drafted the manuscript. All coauthors contributed substantially to interpreting the results, provided important revisions and approved the manuscript. PE acts as guarantor of the present study.
Funding The present study was conducted in the context of the FULGUR project (ANR-19-STPH-003) funded by the French Research Agency in the perspective of the Paris 2024 Olympic and Paralympic Games in collaboration with the French Federation of Athletics, Rugby and Ice Sports, Universities of Nantes, Côte d’Azur, Savoie Mont Blanc, Jean Monnet Saint-Étienne, Saclay, the Mines Saint-Étienne, the CEA and the CNRS. The University Jean Monnet Saint-Étienne and the French Institute of Sport (INSEP) are partners of the French-speaking network ReFORM. ReFORM, and the Amsterdam Collaboration on Health and Safety in Sports (ACHSS) are recognised as Research Centres for the Prevention of Injury and Illness and the Protection of Athletes by the IOC and received funding from the IOC to establish a long-term research programme on the prevention of injuries and illnesses in sports to protect athletes' health.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.